PE20191320A1 - Constructos de vacuna y sus usos contra infecciones causadas por staphylococcus - Google Patents

Constructos de vacuna y sus usos contra infecciones causadas por staphylococcus

Info

Publication number
PE20191320A1
PE20191320A1 PE2019000844A PE2019000844A PE20191320A1 PE 20191320 A1 PE20191320 A1 PE 20191320A1 PE 2019000844 A PE2019000844 A PE 2019000844A PE 2019000844 A PE2019000844 A PE 2019000844A PE 20191320 A1 PE20191320 A1 PE 20191320A1
Authority
PE
Peru
Prior art keywords
seq
polypeptide
amino acid
construct
absent
Prior art date
Application number
PE2019000844A
Other languages
English (en)
Inventor
François Malouin
Celine Ster
Julie Côte-Gravel
Eric Brouillette
Original Assignee
Socpra Sciences Et Genie Sec
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Socpra Sciences Et Genie Sec filed Critical Socpra Sciences Et Genie Sec
Publication of PE20191320A1 publication Critical patent/PE20191320A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

Referido a un constructo de fusion de formula (I): XA-ligante-BZ (I); en donde A y B son, independientemente, un polipeptido que comprende un polipeptido SACOL0029 (SEQ ID NO: 5 y 121 a 131), un polipeptido SACOL0264 (SEQ ID NO: 185), un polipeptido SACOL0442 (SEQ ID NO: 29 y 82 a 92), un polipeptido SACOL0718 (SEQ ID NO: 186), un polipeptido SACOL0720 (SEQ ID NO: 11 y 109 a 120), un polipeptido SACOL1353 (SEQ ID NO: 187), un polipeptido SACOL1416 (SEQ ID NO: 188), un polipeptido SACOL1611 (SEQ ID NO: 189), un SACOL1867 (SEQ ID NO: 152 a 164), un polipeptido SACOL1912 (SEQ ID NO: 43), un polipeptido SACOL1944 (SEQ ID NO: 190), entre otros, sobre la base de la nomenclatura genetica del genoma COL (SACOL) de Staphylococcus aureus expuesto en la Secuencia de Referencia de NCBI NC_002951.2; el ligante es una secuencia de aminoacidos de por lo menos un aminoacido o esta ausente; X esta ausente o es una secuencia de aminoacidos; y Z esta ausente o es una secuencia de aminoacidos. Dicho constructo exhibe una mayor inmunogenicidad, siendo util como vacuna contra la infeccion intramamaria estafilococica (IIM) causada por Staphylococcus aureus. Tambien se refiere a una molecula de acido nucleico que codifica dicho constructo, un vector, una celula huesped que es una forma viva de Staphylococcus aureus y una composicion farmaceutica que comprende dicho constructo.
PE2019000844A 2016-10-21 2017-10-20 Constructos de vacuna y sus usos contra infecciones causadas por staphylococcus PE20191320A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662411120P 2016-10-21 2016-10-21

Publications (1)

Publication Number Publication Date
PE20191320A1 true PE20191320A1 (es) 2019-09-24

Family

ID=62018642

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2019000844A PE20191320A1 (es) 2016-10-21 2017-10-20 Constructos de vacuna y sus usos contra infecciones causadas por staphylococcus

Country Status (24)

Country Link
US (2) US11324815B2 (es)
EP (1) EP3529260A4 (es)
JP (2) JP7181208B2 (es)
KR (1) KR20190082229A (es)
CN (1) CN109843910A (es)
AR (1) AR109847A1 (es)
AU (2) AU2017346974B2 (es)
BR (1) BR112019007796A2 (es)
CA (1) CA3037070A1 (es)
CL (1) CL2019001048A1 (es)
CO (1) CO2019005169A2 (es)
CR (1) CR20190249A (es)
DO (1) DOP2019000102A (es)
IL (1) IL265869A (es)
MX (2) MX2019004539A (es)
MY (1) MY195369A (es)
NZ (1) NZ751880A (es)
PE (1) PE20191320A1 (es)
PH (1) PH12019500843A1 (es)
RU (2) RU2766354C2 (es)
SG (2) SG10201912431XA (es)
TW (1) TW201819402A (es)
UY (1) UY37448A (es)
WO (1) WO2018072031A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220185852A1 (en) * 2020-12-11 2022-06-16 Bayer Animal Health Gmbh Methods and compositions for improved production of an antigen for use in an s. aureus vaccine

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1288774C (en) 1985-01-07 1991-09-10 Deborah A. Eppstein 1,2-dialkoxy-w-trialkylammonium cationic surfactants
US6228844B1 (en) 1991-11-12 2001-05-08 Vical Incorporated Stimulating vascular growth by administration of DNA sequences encoding VEGF
US7060458B1 (en) 1997-08-14 2006-06-13 Wyeth Nucleic acid and amino acid sequences relating to Staphylococcus epidermidis for diagnostics and therapeutics
US6380370B1 (en) 1997-08-14 2002-04-30 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to Staphylococcus epidermidis for diagnostics and therapeutics
US6833134B2 (en) 2000-06-12 2004-12-21 University Of Saskacthewan Immunization of dairy cattle with GapC protein against Streptococcus infection
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
PL229487B1 (pl) 2002-11-12 2018-07-31 Brigham & Womens Hospital Inc Kompozycja zawierająca polimer β-1,6-glukozaminy, kompozycja zawierająca przeciwciało, kompozycja farmaceutyczna, sposób wytwarzania wyodrębnionego polisacharydu, sposób identyfikacji obecności deacetylowanej poli-N-acetyloglukozaminy (dPNAG) i/ lub poli-N-acetyloglukozaminy (PNAG), wyodrębniony polisacharyd do zastosowania w leczeniu lub profilaktyce zakażenia, wyodrębniony polisacharyd do zastosowania do wytwarzania przeciwciał, w tym przeciwciał monoklonalnych, wyodrębniony polisacharyd do zastosowania w identyfikacji przeciwciała monoklonalnego
CN1569893A (zh) 2003-07-21 2005-01-26 中国人民解放军军事医学科学院基础医学研究所 金葡菌毒力因子调控蛋白的抗原表位及其模拟表位和用途
RU2419628C2 (ru) 2004-09-22 2011-05-27 ГлаксоСмитКлайн Байолоджикалз с.а. Иммуногенная композиция для применения в вакцинации против стафилококков
AU2005333603A1 (en) * 2004-10-21 2007-01-04 Wyeth Immunogenic compositions of Staphylococcus epidermidis polypeptide antigens
KR100729954B1 (ko) 2004-12-01 2007-06-20 주식회사 엘지생명과학 Ｓｅｃ１ 변이 단백질의 제형 및 그것의 제형화 방법
WO2008152447A2 (en) 2006-10-30 2008-12-18 The University Of Western Ontario Staphylococcus aureus specific anti-infectives
BRPI1011856A2 (pt) 2009-03-23 2020-11-03 Epitopix, Llc polipeptídeos e composições de imunização contendo polipeptídeos gram-positivos e métodos de uso
NZ612315A (en) * 2009-04-14 2014-10-31 Novartis Ag Compositions for immunising against staphylococcus aureus
PT2547361T (pt) 2010-03-17 2020-12-07 Socpra Sciences Et Genie Sec Componentes de vacina bacteriana de staphylococcus aureus e suas utilizações
MX340446B (es) 2011-06-19 2016-07-08 Univ New York Metodos para tratar y prevenir infecciones por estafilococo dorado y condiciones asociadas.

Also Published As

Publication number Publication date
KR20190082229A (ko) 2019-07-09
RU2022100889A (ru) 2022-04-06
WO2018072031A1 (en) 2018-04-26
US20220288183A1 (en) 2022-09-15
RU2019115303A (ru) 2020-11-23
MX2019004539A (es) 2019-06-12
BR112019007796A2 (pt) 2019-09-03
CL2019001048A1 (es) 2019-08-30
JP7181208B2 (ja) 2022-11-30
AR109847A1 (es) 2019-01-30
MY195369A (en) 2023-01-16
JP2019531100A (ja) 2019-10-31
SG11201901483QA (en) 2019-03-28
CA3037070A1 (en) 2018-04-26
IL265869A (en) 2019-06-30
EP3529260A4 (en) 2020-12-16
AU2017346974A1 (en) 2019-03-14
PH12019500843A1 (en) 2019-12-02
CR20190249A (es) 2019-10-16
US11324815B2 (en) 2022-05-10
CN109843910A (zh) 2019-06-04
TW201819402A (zh) 2018-06-01
MX2023001219A (es) 2023-03-03
US20190216913A1 (en) 2019-07-18
NZ751880A (en) 2023-04-28
JP2023025066A (ja) 2023-02-21
EP3529260A1 (en) 2019-08-28
SG10201912431XA (en) 2020-02-27
UY37448A (es) 2018-03-23
CO2019005169A2 (es) 2019-08-09
DOP2019000102A (es) 2019-07-15
RU2019115303A3 (es) 2021-03-02
AU2017346974B2 (en) 2022-03-31
AU2022204585A1 (en) 2022-07-21
RU2766354C2 (ru) 2022-03-15

Similar Documents

Publication Publication Date Title
CU24570B1 (es) Proteínas de bacillus thuringiensis quiméricas insecticidas tóxicas o inhibidoras de plagas de lepidópteros
ES2722799T3 (es) Vacunas contra el cáncer de cerebro basadas en el péptido alfa 2 del receptor de interleuquina-13
ES2586418T3 (es) Vacuna de proteína de fusión
CY1123189T1 (el) Αντιμικροβiακο πεπτιδιο
JP2014000092A5 (es)
PE20090483A1 (es) Vectores para la expresion multiple de genes
CY1118331T1 (el) Χιμαιρικα πολυπεπτιδια και η χρηση τους στην εκριζωση φορειας βακτηριων
UA116431C2 (uk) Композиція для попередження інфекції mycoplasma spp.
CO6731074A2 (es) Composición vacunal para el control de las infestaciones por ectoparásitos
AR100310A1 (es) Moléculas para transporte de antígeno modular mejoradas y sus usos
PE20191320A1 (es) Constructos de vacuna y sus usos contra infecciones causadas por staphylococcus
MX2009007261A (es) Vacuna de peptido foxp3.
BR112015025285A2 (pt) fator de transcrição artificial, composição farmacêutica, ácido nucleico, vetor, célula hospedeira, célula hospedeira e.coli, portador viral, composição farmacêutica e método de tratamento de atrofia autossômica dominante, atrofia autossômica dominante plus ou glaucoma
CU20210061A7 (es) Composición vacunal que comprende el dominio alfa 3 de mica/b para el tratamiento del cáncer
MX348934B (es) Secuencias de aminoacidos para el control de patogenos.
WO2019033007A3 (en) Staphylococcus pseudintermedius virulence factor compositions
AR056782A1 (es) Uso de polinucleotidos armadillo repeat (arm1) para lograr una resitencia contra agentes patogenos en plantas
WO2014144222A3 (en) Compositions and methods of treating fungal and bacterial pathogens
BR112022010228A2 (pt) Vacinas de parasita de leishmania viva atenuada com características de segurança aumentadas
BR102013026625A8 (pt) vacina de peptídeos recombinantes para o controle de carrapatos e sequências de nucleotídeos codificadoras dos peptídeos recombinantes
AR102120A1 (es) Interferón modificado con inmunogenicidad reducida
CL2017002972A1 (es) Péptido anti microbiano del tipo nk-lisina, para el control de agentes patógenos y su uso como adyuvante molecular.
PL405911A1 (pl) Białko o aktywności hydrolitycznej wobec polisacharydowych otoczek bakteryjnych, polinukleotyd kodujący to białko, biologicznie czynny wektor, kompozycja zawierająca białko i jego zastosowanie
BR112019008624A2 (pt) uso de um peptídeo secretagogo do hormônio do crescimento, composição de vacina, e, método para melhorar a resposta imune contra um antígeno de vacina.
RU2016152819A (ru) Гибридные рекомбинантные полипептиды для производства вакцины против Streptococcus agalactiae